Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
Author: Ben Barron-Millar, Senior Consultant, Value Communication The National Institute for Health and Care Excellence (NICE) has published its Annual […]
Insights
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
Author: Ben Barron-Millar, Senior Consultant, Value Communication A summary of NICE’s disease-specific reference case extension for managing overweight and obesity
Winning in a Changing HTA Landscape: What HTAi 2026 Means for Strategy, Evidence, and Access
At HTAi 2026 in Istanbul, one message came through clearly: delivering high-quality health technology assessment (HTA) is no longer the
Two EU JCAs Discontinued This Week! What Happened & Why It Matters
The EU HTA Regulation (EU) 2021/2282 was designed to transform clinical assessment in Europe through Joint Clinical Assessments (JCAs). But
Whitepaper: Why Oncology Strategy Must Now Start Earlier, Think Wider, and Integrate Market Access from the Beginning
Strategic Implications for Pharma & Biotech from ASCO 2026 Author: Univ.-Prof. Dr. Matthias P. Schönermark, Chief Strategy Officer Every
The Empty Grid: What Europe’s First JCA Really Tells Us About Launch Readiness
Authors: Prof. Dr. Matthias Schonermark, Chief Strategy Officer & Sebastian Vinzens, Senior Medical Writer The first EU JCA should not
ISPOR US 2026: Why Europe Increasingly Shapes Your Global Market Access Strategy
Authors: Ben Hendry, Director, Global Business Development & Ruth Howells, Country Manager, UK & Ireland At ISPOR US 2026 in Philadelphia,
Bringing Clarity to Article 10: What the New Belgian FAMHP Guidance Means for Pharma
Author: Wim Neckebroek, Director, Regulatory Affairs The Belgian Federal Agency for Medicines and Health Products (FAMHP) has introduced new guidance
Germany’s New Savings Law Advances: What the Cabinet Draft Means for AMNOG and Market Access
Author: Florian Stieglitz, Consultant, Market Access Germany’s draft contribution rate stabilization law for the statutory health insurance system (GKV-Beitragssatzstabilisierungsgesetz) has
Between Ambition and Reality: Why German Routine Practice Data Collection Often Stalls
Author: Lukas Schoppmeyer, Senior Consultant, Market Access Since 2019, following the adoption of the German Act for greater safety in the provision of medicinal products (GSAV), Section 35a
